




Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.

Journal Pre-proof



Immunity Acquired From the First Wave of COVID-19 Against Reinfections Up to Omicron Predominance

Fan-Yun Lan, MD, PhD, Stephen D. Kasteler, MD, MPH, Amalia Sidossis, MD, Eirini Iliaki, MD, MPH, Jane Buley, RN, Neetha Nathan, Rebecca Osgood, MD, Lou Ann Bruno-Murtha, DO, Stefanos N. Kales, MD, MPH

PII: S0025-6196(22)00620-6

DOI: <https://doi.org/10.1016/j.mayocp.2022.11.002>

Reference: JMCP 3991

To appear in: *Mayo Clinic Proceedings*

Received Date: 22 May 2022

Revised Date: 2 October 2022

Accepted Date: 3 November 2022

Please cite this article as: Lan FY, Kasteler SD, Sidossis A, Iliaki E, Buley J, Nathan N, Osgood R, Bruno-Murtha LA, Kales SN, Immunity Acquired From the First Wave of COVID-19 Against Reinfections Up to Omicron Predominance, *Mayo Clinic Proceedings* (2022), doi: <https://doi.org/10.1016/j.mayocp.2022.11.002>.

This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of record. This version will undergo additional copyediting, typesetting and review before it is published in its final form, but we are providing this version to give early visibility of the article. Please note that, during the production process, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

© 2022 Published by Elsevier Inc on behalf of Mayo Foundation for Medical Education and Research

Immunity Acquired From the First Wave of COVID-19 Against Reinfections Up to Omicron Predominance

Fan-Yun Lan, MD, PhD^{1,2,3,4}; Stephen D. Kasteler, MD, MPH^{2,5}, Amalia Sidossis, MD^{1,2}; Eirini Iliaki, MD, MPH^{1,6}; Jane Buley, RN¹; Neetha Nathan¹; Rebecca Osgood, MD^{7,8}; Lou Ann Bruno-Murtha, DO⁶; Stefanos N. Kales, MD, MPH^{1,2}

1 Occupational Medicine, Cambridge Health Alliance, Harvard Medical School, Cambridge MA, USA

2 Department of Environmental Health, Harvard University T.H. Chan School of Public Health, Boston, MA, USA

3 Department of Occupational and Environmental Medicine, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan, Taiwan

4 Institute of Health and Welfare Policy, National Yang Ming Chiao Tung University, Taipei, Taiwan

5 Maj, USAF, MC, FS; Air Force Institute of Technology, Wright-Patterson AFB, OH, USA

6 Infection Prevention and Infectious Diseases, Cambridge Health Alliance, Harvard Medical School, Cambridge MA, USA

7 Pathology, Cambridge Health Alliance, Harvard Medical School, Cambridge MA, USA

8 Pathology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA

Financial support: None reported.

Conflict of interest disclosure: S.N.K. has received COVID-19-related consulting fees from Open Health and has owned shares of Regeneron, Moderna and Astra-Zeneca. All other authors declare no competing interests.

Corresponding author: Stefanos N. Kales MD, MPH,
Occupational Medicine, Cambridge Health Alliance, Macht Building 427
1493 Cambridge Street, Cambridge, MA 02139
Tel. 617/665-1580 Fax. 617/665-1672
E-mail: skales@hsph.harvard.edu

Word count: 500

Number of references: 5

Number of figures: 1

Letter to the Editor**Immunity Acquired From the First Wave of COVID-19 Against Reinfections Up to Omicron Predominance**

To the Editor: The protective effects of prior infection with SARS-CoV-2 against re-infection are of great public health interest. Among the limited literature covering delta and omicron variant predominance, a nation-wide study in Qatar shows the protective effects derived from prior infection are 92% and 56% against the delta and omicron variants, respectively.¹ Malato et al. found a previous infection could have 50–75% protective effects against the most recent BA.5 variant re-infection, with the greatest protection from previous BA.1/BA.2 omicron infection.² Cerqueira-Silva et al., on the other hand, found a relatively low (28.9%) protective effect of past infection against omicron infection, although better against severe outcomes (85.6%).³ However, these existing studies may have misclassified individuals having contracted SARS-CoV-2 but without symptoms and not having a diagnostic test as lacking prior infection. Therefore, we conducted this study to follow a cohort of healthcare workers (HCWs) in a Massachusetts-based healthcare system with baseline serology testing results available during the first wave of the pandemic,⁴ accounting for potential confounders (i.e., age, sex, ethnicity,⁵ and the time from taking serology test to getting the first COVID-19 vaccine dose). Because the HCWs had received vaccines with various efficacies, we adjusted for their intention to be vaccinated instead of treating vaccination as a time-dependent

variable.

Each HCW was followed from the date of serology testing to his/her termination date, the date of a subsequent positive PCR assay, or February 28, 2022 (about 1.5 years follow-up). Those with either a positive baseline IgG, IgM or IgA were considered seropositive and compared to seronegative staff. The Kaplan-Meier survival curve was used to delineate the infection-free trends across the groups (Figure). After visually inspecting the log(-log) plot, we built the Schemper's weighted Cox regression models for survival analyses to account for the non-proportionality and further adjusted for potential confounders. The study was exempted for human subjects research by the Cambridge Health Alliance Institutional Review Board (4/29/202-003).

Among 176 eligible HCWs, the eighty-six (48.9%) seropositives were younger (44.7 ± 11.7 vs. 48.3 ± 11.9 , $P=.04$), more likely to be men (27.9% vs. 12.2%, $P=.02$), ethnic minority (white: 30.2% vs. 53.3%, $P<.001$), and tended to get their first COVID-19 vaccine dose later (time to first shot: 282.6 ± 99.9 vs. 203.0 ± 80.2 days, $P<.001$). After adjusting for potential confounders, HCWs with baseline positive serology results had a reduced hazard ratio, 0.13 (95% CI: 0.05- 0.39), for contracting SARS-CoV-2 throughout the follow-up period. The findings remained robust after excluding those with equivocal serology results at baseline.

While limited by a lack of statistical power that prevents us from performing stratified analyses for different variant predominance, unmeasured confounding such as household

situation and testing behaviors, and different serology tests to determine the baseline serology results (there were two labs using different assay techniques), our study highlights the protective effects of immunity conferred by infection throughout periods covering the variants of interest, in agreement with existing literature, while using serology results in the first wave as a more rigorous measure to determine prior infection status.

Fan-Yun Lan, MD, PhD

Harvard Medical School

Cambridge, Massachusetts, USA

Harvard University T.H. Chan School of Public Health,

Boston, Massachusetts, USA

National Cheng Kung University,

Tainan, Taiwan

National Yang Ming Chiao Tung University

Taipei, Taiwan

Stephen D. Kasteler, MD, MPH

Harvard University T.H. Chan School of Public Health,

Boston, Massachusetts, USA

Air Force Institute of Technology,

Wright-Patterson AFB, Ohio, USA

Amalia Sidossis, MD

Harvard Medical School

Cambridge, Massachusetts, USA

Harvard University T.H. Chan School of Public Health,

Boston, Massachusetts, USA

Eirini Iliaki, MD, MPH

Harvard Medical School

Cambridge, Massachusetts, USA

Cambridge Health Alliance, Harvard Medical School,

Cambridge, Massachusetts, USA

Jane Buley, RN
Harvard Medical School
Cambridge, Massachusetts, USA

Neetha Nathan
Harvard Medical School
Cambridge, Massachusetts, USA

Rebecca Osgood, MD
Cambridge Health Alliance, Harvard Medical School,
Cambridge, Massachusetts, USA
Massachusetts General Hospital,
Harvard Medical School
Boston, Massachusetts, USA

Lou Ann Bruno-Murtha, DO
Cambridge Health Alliance, Harvard Medical School,
Cambridge, Massachusetts, USA

Stefanos N. Kales, MD, MPH
Harvard Medical School
Cambridge, Massachusetts, USA
Harvard University T.H. Chan School of Public Health,
Boston, Massachusetts, USA

References

1. Altarawneh HN, Chemaitelly H, Hasan MR, et al. Protection against the omicron variant from previous SARS-CoV-2 infection. *N Engl J Med*. 2022;386(13):1288-1290. doi:10.1056/NEJMc2200133
2. Malato J, Ribeiro RM, Leite PP, et al. Risk of BA.5 infection among persons exposed to previous SARS-CoV-2 variants. *N Engl J Med*. 2022;387(10):953-954. doi:10.1056/NEJMc2209479
3. Cerqueira-Silva T, de Araujo Oliveira V, Paixão ES, et al. Vaccination plus previous infection: Protection during the omicron wave in Brazil. *Lancet Infect Dis*. 2022;22(7):945-946. doi:10.1016/S1473-3099(22)00288-2
4. Bruno-Murtha LA, Osgood R, Lan FY, et al. SARS-CoV-2 antibody seroprevalence after the first wave among workers at a community healthcare system in the Greater Boston area. *Pathog Glob Health*. 2021;115(5):331-334. doi:10.1080/20477724.2021.1901041
5. Lan FY, Filler R, Mathew S, et al. Sociodemographic risk factors for coronavirus disease 2019 (COVID-19) infection among Massachusetts healthcare workers: A retrospective cohort study. *Infect Control Hosp Epidemiol*. 2021;42(12):1473-1478. doi:10.1017/ice.2021.17

Figure. The Kaplan-Meier curve for the COVID-19 infection-free person-days across the populations based on their baseline serology testing results in the first wave

Journal Pre-proof

